Understanding LC-MS Based Bioanalysis Approaches to Determine REGN5093-M114 DAR in Clinical PK Samples
- Introducing REGN5093-M114 ADC with M114 linker-payload and bispecific antibody targeting two MET epitopes
- Outlining exploratory objective of first-in-human study to assess DAR changes in patient plasma samples following intravenous administration
- Developing LC-MRM-MS based assays to monitor average DAR changes and an IP-intact MS method to characterize payload distribution in PK samples